Glycoengineered type II anti-CD20 monoclonal antibody that depletes B cells through enhanced ADCC/ADCP and direct cell death, with reduced complement activation.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced Fc gamma RIIIa–mediated ADCC and ADCP, along with direct caspase-independent cell death, with relatively reduced complement-dependent cytotoxicity.
YES
DIRECT
Binds CD20 on B cells, recruiting effector cells for ADCC (via Fc-gamma RIIIa) and ADCP, and also induces direct caspase-independent cell death; complement cytotoxicity is limited.
Humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1); activates NK cells and mediates antibody-dependent cellular cytotoxicity against myeloma cells.
Humanized IgG1 monoclonal antibody that binds SLAMF7 (CS1) on myeloma and NK cells; activates NK cells and induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7-expressing myeloma cells.
YES
DIRECT
Elotuzumab binds SLAMF7 on myeloma cells and engages/activates NK cells via Fc gamma receptors (CD16) and SLAMF7 on NK cells, triggering antibody-dependent cellular cytotoxicity to lyse SLAMF7+ tumor cells.
A CD19-targeting antibody-drug conjugate consisting of a human monoclonal IgG linked to a pyrrolobenzodiazepine (PBD) prodrug. Administered intravenously on Day 1 of 21-day cycles. The anti-CD19 antibody binds CD19 on B cells, is internalized, and releases an activated PBD payload that forms DNA interstrand crosslinks, blocking replication/transcription and inducing apoptosis in CD19-positive malignant B lymphocytes.
CD19-targeting monoclonal antibody-drug conjugate; after binding CD19 on B cells and internalization, a tumor-cleavable linker is processed to release a PBD payload that forms DNA interstrand crosslinks, blocking replication/transcription and inducing apoptosis in CD19-positive malignant B lymphocytes.
YES
DIRECT
The ADC binds CD19 on target cells, is internalized, and the linker is cleaved in lysosomes to release a PBD payload that forms DNA interstrand crosslinks, blocking replication/transcription and triggering apoptosis of CD19+ cells.
A CD19-targeting antibody-drug conjugate consisting of a human monoclonal IgG linked to a pyrrolobenzodiazepine (PBD) prodrug. Administered intravenously on Day 1 of 21-day cycles. The anti-CD19 antibody binds CD19 on B cells, is internalized, and releases an activated PBD payload that forms DNA interstrand crosslinks, blocking replication/transcription and inducing apoptosis in CD19-positive malignant B lymphocytes.
CD19-targeting monoclonal antibody-drug conjugate; after binding CD19 on B cells and internalization, a tumor-cleavable linker is processed to release a PBD payload that forms DNA interstrand crosslinks, blocking replication/transcription and inducing apoptosis in CD19-positive malignant B lymphocytes.
NO
INDIRECT
IKS03 binds CD19 on B cells, is internalized, and releases a PBD payload that crosslinks DNA in the minor groove, blocking replication/transcription and inducing apoptosis of CD19+ cells; DNA minor-groove binding is not the targeted antigen for cell selectivity.
Anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated antibody-dependent cellular cytotoxicity; it can also trigger apoptosis of CD20+ cells.